An update of OS data (secondary endpoint) in 2021 showed that 67% of patients in the surveillance group were alive after 3 years versus 79% in the chemotherapy group, but reduction in the relative risk of death did not reach statistical significance (HR = 0.72; 95% CI: 0.47–1.08; p = 0.11).
← all excerpts
Clinical and Biological Differences between Upper Tract Carcinoma and Bladder Urothelial Cancer, Including Implications for Clinical Practice.
1
0.1100
0.1100